Drug companies Boehringer Ingelheim, AstraZeneca and GSK have announced they are capping out-of-pocket costs for their inhaler products at $35 per month. INHALE applauds all three companies for their decision! This will help reduce the financial burden for many people who use inhalers to treat asthma and COPD. Price caps for Boehringer Ingelheim and AstraZeneca inhalers go into effect on June 1, 2024. GSK says it will implement its price caps no later than January 1, 2025.
AstraZeneca also says it substantially reduced the list price for Symbicort starting Jan. 1, 2024.
The price caps will apply at retail pharmacies. They should be particularly helpful for people who are uninsured or underinsured. Boehringer Ingelheim, AstraZeneca and GSK say they will continue to offer patient assistance programs, discounts and rebates for inhalers. The companies say they cannot control any inhaler fees added on by pharmacy benefit managers.
*For eligible patients. Terms and conditions apply. Government restrictions exclude people enrolled in federal government insurance programs from co-pay support. Please refer to each pharmaceutical company announcement for details.
INHALE prepares regular PO and Clinical level newsletters that contain:
Support for the INHALE CQI is provided by Blue Cross Blue Shield of Michigan as part of the BCBSM Value Partnerships program. BCBSM’s Value Partnerships program provides clinical and executive support for all CQI programs.
Although Blue Cross Blue Shield of Michigan and the INHALE CQI work in partnership, the opinions, beliefs, and viewpoints expressed by INHALE CQI do not necessarily reflect the opinions, beliefs, and viewpoints of BCBSM or any of its employees.